0001495809-14-000002.txt : 20141120 0001495809-14-000002.hdr.sgml : 20141120 20141120151513 ACCESSION NUMBER: 0001495809-14-000002 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20141120 DATE AS OF CHANGE: 20141120 EFFECTIVENESS DATE: 20141120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: X2 Biosystems, Inc. CENTRAL INDEX KEY: 0001495809 IRS NUMBER: 272327516 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-215845 FILM NUMBER: 141238794 BUSINESS ADDRESS: STREET 1: 1927 POST ALLEY STREET 2: SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98101 BUSINESS PHONE: 206-351-0004 MAIL ADDRESS: STREET 1: 1927 POST ALLEY STREET 2: SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98101 FORMER COMPANY: FORMER CONFORMED NAME: X2Impact, Inc. DATE OF NAME CHANGE: 20100701 D/A 1 primary_doc.xml X0707 D/A LIVE 0001495809 X2 Biosystems, Inc. 1927 POST ALLEY SUITE 200 SEATTLE WA WASHINGTON 98101 206-351-0004 WASHINGTON X2Impact, Inc. Corporation true 2010 Richard Able 1927 Post Alley Suite 200 Seattle WA WASHINGTON 98101 Executive Officer Director Robert G. Rosen 1927 Post Alley Suite 200 Seattle WA WASHINGTON 98101 Director Chris Siege 1927 Post Alley Suite 200 Seattle WA WASHINGTON 98101 Director John Ralston 1927 Post Alley Suite 200 Seattle WA WASHINGTON 98101 Executive Officer Director Chief Executive Officer Biotechnology $1,000,001 - $5,000,000 06b true 0001495809-14-000001 2014-04-07 false true true true Debt convertible into stock of issuer. false 50000 J.P. Turner & Company, L.L.C. 43177 None None 3060 Peachtree Rd. NW 11th Floor Atlanta GA GEORGIA 30305 AL ALABAMA CT CONNECTICUT FL FLORIDA IL ILLINOIS LA LOUISIANA MS MISSISSIPPI NJ NEW JERSEY RI RHODE ISLAND TN TENNESSEE TX TEXAS WY WYOMING false 9000000 4220000 4780000 false 41 330600 true 0 true 8% sales concession, 5% management fee, 7 year Common Stock purchase warrant equal to 10% of the offering proceeds. Agent to receive fully vested common stock equal to 10% of the offering proceeds. Agent received $211,000 in management fees. 140000 true false X2 Biosystems, Inc. John Ralston John Ralston CEO and Director 2014-11-18